Correction of pathology in mice displaying Gaucher disease type 1 by a clinically-applicable lentiviral vectorMaria Dahl, Stefan Karlsson, Emma Smith et al.|Molecular Therapy — Methods & Clinical Development|2020Cited by 23
Screening chimeric GAA variants in preclinical study results in hematopoietic stem cell gene therapy candidate vectors for Pompe diseaseYildirim Dogan, Niek P. van Til, John K. Yoon et al.|Molecular Therapy — Methods & Clinical Development|2022Cited by 16
Preclinical lentiviral hematopoietic stem cell gene therapy corrects Pompe disease-related muscle and neurological manifestationsJohn K. Yoon, Niek P. van Til, Jeffrey W. Schindler et al.|Molecular Therapy|2024Cited by 5
Screening of Chimeric GAA Variants in a Preclinical Study of Pompe Disease Results in Candidate Vector for Hematopoietic Stem Cell Gene TherapyYildirim Dogan, Niek P. van Til, Cecilia Barese et al.|bioRxiv (Cold Spring Harbor Laboratory)|2021Cited by 2
Flow Cytometry Assay to Monitor Effectiveness of Gene Therapy Correction in Peripheral Blood Mononuclear Cells of Gaucher Disease Type I PatientsCecilia Barese, Chris Mason, Michael T. Waring et al.|Blood|2018Cited by 1